|courtesy of HIVplusmag.com|
"This new drug indication is the baseline, or building block, for a new type of biomedical HIV prevention," said Marjorie Hill, PhD, Chief Executive Officer of GMHC. "PrEP drug development can be added to the vast array of HIV prevention tools including condoms, HIV testing and Post-Exposure Prophylaxis (PEP). Truvada as PrEP will clearly be one of the first iterations for Treatment as Prevention (TasP). While we do not have all the necessary information about how the public will respond and potentially utilize this medication for prevention; our constituents, clients, family and loved ones deserve complete support to advance HIV prevention."
PrEP, as it stands now, is not the last car on the train. It is just the beginning. And GMHC fully supports the FDA in clearing the way for this new indication of ART. This drug utilization is a step forward in the development of an array of tools that each person who perceives themselves at-risk for contracting HIV may utilize in their cadre to protect his or her health. HIV is a virus that when left untreated will ultimately kill each person it infects. Thus, GMHC adamantly supports the development of any modality that will treat the infected person and also any modality that will hinder HIV-acquisition for an uninfected person. Each available tool helps stop HIV in its tracks. And Together We Can make this an "AIDS-Free Generation" as President Obama declared.